Document is current
Any future updates will be listed below
-
Authors
Ku, Zhiqiang https://orcid.org/0000-0001-8347-0013
Xie, Xuping https://orcid.org/0000-0003-0918-016X
Lin, Jianqing https://orcid.org/0000-0003-4336-9003
Gao, Peng
Wu, Bin https://orcid.org/0000-0002-0883-8006
El Sahili, Abbas https://orcid.org/0000-0003-3973-686X
Su, Hang
Liu, Yang
Ye, Xiaohua https://orcid.org/0000-0002-2300-4739
Tan, Eddie Yongjun
Li, Xin
Fan, Xuejun
Goh, Boon Chong
Xiong, Wei
Boyd, Hannah
Muruato, Antonio E.
Deng, Hui
Xia, Hongjie https://orcid.org/0000-0002-2520-7038
Zou, Jing
Kalveram, Birte K.
Menachery, Vineet D. https://orcid.org/0000-0001-8803-7606
Zhang, Ningyan https://orcid.org/0000-0002-4348-2180
Lescar, Julien https://orcid.org/0000-0002-9623-8130
Shi, Pei-Yong https://orcid.org/0000-0001-5553-1616
An, Zhiqiang https://orcid.org/0000-0001-9309-2335
- License Information
-
More Information
Article History
Received: 18 February 2022
Accepted: 12 September 2022
First Online: 22 September 2022
Competing interests
: The University of Texas System has filed a patent on the SARS-CoV-2 IgG antibodies and the reverse genetic system and reporter SARS-CoV-2. X.X., Z.K., N.Z., P.-Y.S., and Z.A. are listed as co-inventors of the patent application. The remaining authors declare no competing interests.
